---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-043544"
form_type: "8-K"
ticker: "AKTX"
cik: "0001541157"
company_name: "Akari Therapeutics Plc"
filed_at: "2025-03-03T23:59:59+00:00"
generated_at: "2026-05-25T17:42:42.355258+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Akari Therapeutics raises ~$7.1M via ADS/warrant offering with board participation

## Summary
- Gross proceeds ~$7.1M from sale of 6,637,626 ADS units (or prefunded warrants) plus Series A/B warrants; includes $1M note termination by Chairman.
- ADS unit purchase price: $0.87 plus $0.25–$0.3125 premium per tier; warrants exercisable at $0.87.
- Series A warrants expire 1 year, Series B warrants expire 5 years from closing.
- Chairman Dr. Hoyoung Huh, CEO Dr. Samir Patel, and all board members participating; $1M note terminated.
- Proceeds for working capital; resale registration statement to be filed within 60 days of closing (expected March 5).

## SEC filing metadata
- accession: 0001193125-25-043544
- form_type: 8-K
- ticker: AKTX
- cik: 0001541157
- company_name: Akari Therapeutics Plc
- filed_at: 2025-03-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1541157/000119312525043544/0001193125-25-043544-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1541157/000119312525043544/d803084d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-043544
- JSON: https://secwatch.observer/filing/0001193125-25-043544.json
- Plain text: https://secwatch.observer/filing/0001193125-25-043544.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.